Key Highlights
INVEGA and VRAYLAR (US)/REAGILA (EU) (cariprazine) accounted for the major share of the revenue market for schizophrenia patients in 2023. However, according to DelveInsight, this share is expected to decline by 2034 due to the launch of new emerging therapies.
Schizophrenia has a robust drug development pipeline, which targets glycine transporter, D-amino acid oxidase (DAAO) inhibitor, or other neurotransmitter systems involved in schizophrenia that are expected to influence market dynamics.
A few potential emerging schizophrenia therapies such as Boehringer Ingelheim’s Iclepertin (BI-425809), Sumitomo Pharma America/Otsuka Pharmaceutic...